Campbell Hy
Family · Arlington, TXNPI 1902405798
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,441 of the $3,743 with a category attached, or 65.2%. Myriad Genetic Laboratories, Inc. accounts for 69.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $1,919 and has fallen 76.5% since, to $450 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $73.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$3K
- Incyte Corporation$292
- GSK$112
- Daiichi Sankyo Inc.$104
- G1 Therapeutics, Inc.$95
- AstraZeneca$86
- plus $471 from 12 others
What the payments were for
- Speaking & faculty fees$1,13830%
- Food & beverage$2,44165%
- Education$1654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 26 | $2,583 |
| Incyte Corporation | 5 | $292 |
| GSK | 1 | $112 |
| Daiichi Sankyo Inc. | 1 | $104 |
| G1 Therapeutics, Inc. | 1 | $95 |
| AstraZeneca | 1 | $86 |
| Astellas Pharma US Inc | 2 | $84 |
| Seagen Inc. | 1 | $83 |
| Gilead | 1 | $50 |
| AbbVie | 2 | $40 |
| Array Biopharma Inc | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Novartis | 2 | $31 |
| Johnson & Johnson | 1 | $28 |
| Bayer | 1 | $22 |
| Morphosys, US Inc. | 1 | $22 |
| Stryker | 1 | $21 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$1,617
- PreciseTumor$131
- JAKAFI$129
- ZEJULA$112
- Enhertu$104
How this compares
$3,743 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Triamcinolone Acetonide | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Other family in Arlington
- Nadia WinstonArlington$32K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.